Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
We compared the long-term immunologic and virologic efficacy of the dual- and triple-nucleoside therapy for HIV infection. This was a retrospective analysis of 2 randomized clinical trials in antiretroviral-naive patients. In the dual-nucleoside group, 15 started with didanosine (ddI) monotherapy and then added stavudine (d4T) after 24 weeks, 63 started with various doses of d4T and ddI, and 53 started with zidovudine (ZDV) and lamivudine (3TC). In the triple-nucleoside group, 53 started with ZDV, 3TC, and ddI. After 48 weeks, patients who were not failing were randomized to immediate (before treatment failure) versus delayed (at the time of virologic failure) switching from ddI and d4T to ZDV and 3TC or vice versa and from ZDV, 3TC, and ddI to d4T, 3TC, and abacavir (ABC). Failure was defined as a plasma HIV-1 RNA level>or=1 log10 above nadir or >or=10,000 copies/mL when nadir was <500 copies/mL. Patients failing therapy before week 48 received the new treatment as in the immediate switching group. Hydroxyurea was added to the last treatment regimen if patients failed after week 96. CD4 count and plasma HIV-1 RNA level (branched DNA assay with a cutoff point of 50 copies/mL) at week 144 were analyzed by intention to treat. Compared with the dual-nucleoside group, the triple-nucleoside group had a higher proportion of patients with <50 copies/mL at 144 weeks (60% vs. 18%; P<0.001), higher median CD4 count (388 cells/microL vs. 346 cells/microL; P=0.018), and longer duration of response, defined as the time from onset of viral suppression (<500 copies/mL) to the time of treatment failure (the first of 2 consecutive HIV-1 RNA measurements >500 copies/mL never followed by 2 consecutive visits showing suppressible viremia to <500 copies/mL) or discontinuation from the study (144 weeks vs. 104 weeks; P=0.002). Multivariate regression analyses showed that significant predictors for treatment success, defined as a plasma viral load <50 copies/mL at week 144, were asymptomatic clinical status at enrollment, a baseline plasma viral load <or=30,000 copies/mL, treatment with triple nucleosides, and a viral load response of <500 copies/mL by week 12. Triple-nucleoside therapy with ZDV, 3TC, and ddI or d4T, 3TC, and ABC in patients with HIV infection is more effective in inducing a sustained virologic response than the dual combinations of ZDV and 3TC or ddI and d4T.
Ungsedhapand
Chaiwat
C
HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand. chaiwat.u@chula.ac.th
Srasuebkul
Preeyaporn
P
Cardiello
Peter
P
Ruxrungtham
Kiat
K
Ratanasuwan
Winai
W
Kroon
Eugene D M B
ED
Tongtalung
Metta
M
Juengprasert
Nittaya
N
Ubolyam
Sasiwimol
S
Siangphoe
Umaporn
U
Emery
Sean
S
Lange
Joep M A
JM
Cooper
David A
DA
Phanuphak
Praphan
P
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage; D015224:Dideoxynucleosides / Q000008:administration & dosage; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D008297:Male; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D018119:Stavudine / Q000008:administration & dosage; D013785:Thailand; D013997:Time Factors; D015215:Zidovudine / Q000008:administration & dosage; D000099227:Abacavir
D019380:Anti-HIV Agents; D016049:Didanosine; D015224:Dideoxynucleosides; D019259:Lamivudine; D012367:RNA, Viral; D018119:Stavudine; D015215:Zidovudine; D000099227:Abacavir